Reports
Sale
Ataxia Market Size, Share, Trends, Analysis Growth, Forecast: By Type: Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, Others (Multiple System Atrophy (MSA); By Service: Treatment, Diagnosis; By Dosage Form: Solid, Liquids, Others; By Age Group: Adult, Child, Geriatric; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Ataxia Market Outlook
The ataxia market size was valued at USD 37.7 billion in 2023, driven by intensive research activities to develop effective drugs and therapies across the 8 major markets. The market is expected to grow at a CAGR of 9.72% during the forecast period of 2024-2032, with the values likely to rise from USD 41.3 billion in 2024 to USD 95.3 billion by 2032.
Ataxia Market Overview
Ataxia is a neurological condition characterized by loss of muscle control in the arms and legs of a patient. Lack of balance and coordination often results in trouble walking. The condition can also affect fingers, speech, and eye movements in the patients. Ataxia may appear suddenly due to some head injury, stroke, infections, etc., or develop gradually due to alcohol abuse, hypothyroidism, exposure to certain drugs, etc. It can be sporadic, hereditary, or acquired, with Friedreich ataxia being the most common hereditary form, affecting one in every 50,000 people in the United States.
Ataxia has a prevalence of 26 cases per 100,000 children , while hereditary ataxias affect 10 per 100,000 individuals. The increasing incidence is anticipated to boost the ataxia market share in the forecast period. Moreover, the regions with consanguinity (mating between blood relatives) as a common practice show a high prevalence of the disorder. In addition, a surge in drug approvals by the health authorities and robust research activities to find treatment options are driving the growth of the market.
Surge in Drug Approvals to Offer Advanced Treatment Alternatives
The increasing number of drug approvals by the health authorities to address ataxia-associated morbidities is contributing to the ataxia market growth. In February 2023, the United States Food and Drug Administration (FDA) approved Reata Pharmaceuticals, Inc.'s Skyclarys (omaveloxolone), developed by as the first treatment for Friedreich’s ataxia. The efficacy of the drug was tested in a 48-week randomized, placebo-controlled, and double-blind study of 103 patients with the neuromuscular condition, which yielded positive results.
Skyclarys reached another milestone in December 2023 when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive response to its marketing authorization in the European Union. Upon the approval by the European Commission (EC), Skyclarys will be the first authorized treatment within the region for people aged 16 years or more, which can slow the progression of Friedreich’s ataxia.
Intensive Research Activities to Address Increasing Ataxia Market Demand
As Friedreich’s ataxia is the most common type of inherited ataxia, research activities aimed at finding promising therapeutic treatments are being promoted to reduce ataxia-associated healthcare burden. In April 2023 , an investigative study on the role of adenosine (a widely distributed nucleoside in the central nervous system) was conducted to evaluate its role in mitigating mitochondrial impairment in patients with Friedreich’s ataxia. The results demonstrated that adenosine could counter the deleterious effects of mitochondrial dysfunction and oxidative stress by regulating mitochondrial function and biogenesis in the fibroblasts of a patient with Friedreich’s ataxia. The results of the study support adenosine as a potential therapeutic in the treatment of this neuromuscular disease.
Other interventions such as stem cell therapy are also receiving attention from researchers for ataxia treatment. In addition, the treatment of spinocerebellar ataxia with mesenchymal stem cells is under investigation, projected to contribute to boost the market size in the forecast period.
Ataxia Market Segmentation
Market Breakup by Type
- Spinocerebellar Ataxias
- Ataxia-Telangiectasia
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA)
Market Breakup by Service
- Treatment
- Diagnosis
Market Breakup by Dosage Form
- Solid
- Liquids
- Others
Market Breakup by Age Group
- Adult
- Child
- Geriatric
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Ataxia Market Regional Analysis
The United States is anticipated to lead the ataxia market, owing to the presence of prominent biopharmaceutical companies, working to offer better treatment alternatives. In May 2023 , a Biohaven Ltd. announced the submission of a new drug application (NDA) for troriluzole to the United States FDA. The novel drug was designed to treat Spinocerebellar Ataxia Type 3 (SCA3) in patients.
Europe is also witnessing increased funding and investments by various sectors to accommodate the growing ataxia market demand. In January 2024 , Vico Therapeutics B.V., a clinical-stage genetic medication company based in the Netherlands, announced USD 60 million Series B financing. The funding is aimed to support the ongoing Phase 1/2a clinical trial of its intrathecally administered product VO659, designed to treat patients affected with spinocerebellar ataxia type 3 and type 1, among other neurological diseases.
Ataxia Market: Competitor Landscape
In July 2023, a global biotechnology company Biogen Inc. acquired Reata Pharmaceuticals, Inc. to accelerate the commercialization of the drug Skyclarys to patients with Friedreich’s ataxia around the world. Biogen agreed to buy Reata for USD 172.50 per share in cash, equivalent to a total enterprise value of around USD 7.3 billion. The market has been witnessing similar events of collaborations and acquisitions to deliver innovative therapies in the areas of unmet medical needs. Consequently, this is expected to propel ataxia market share in the coming years.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Merck KGaA
- Aurobindo Pharma
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical
- Acorda Therapeutics
- Viatris Inc.
- Design Therapeutics Inc.
- Lupin
- Apotex Inc.
- Biohaven Pharmaceuticals
- Amneal Pharmaceuticals LLC.
- Biovista
- Intrabio
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Service |
|
| Breakup by Dosage Form |
|
| Breakup by Age Group |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ataxia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ataxia Epidemiology Analysis – 8 Major Markets
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Ataxia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Ataxia Epidemiology Forecast (2017-2032)
5.3.1 Germany Ataxia Epidemiology Forecast (2017-2032)
5.3.2 France Ataxia Epidemiology Forecast (2017-2032)
5.3.3 Italy Ataxia Epidemiology Forecast (2017-2032)
5.3.4 Spain Ataxia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Ataxia Epidemiology Forecast (2017-2032)
5.4 Japan Ataxia Epidemiology Forecast (2017-2032)
5.5 China Ataxia Epidemiology Forecast (2017-2032)
6 Ataxia Market Overview – 8 Major Markets
6.1 Ataxia Market Historical Value (2017-2023)
6.2 Ataxia Market Forecast Value (2024-2032)
7 Ataxia Market Landscape – 8 Major Markets*
7.1 Ataxia Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ataxia Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Service
7.2.3 Analysis by Dosage Form
8 Ataxia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ataxia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ataxia Market Segmentation – 8 Major Markets
11.1 Ataxia Market by Type
11.1.1 Market Overview
11.1.2 Spinocerebellar Ataxias
11.1.3 Ataxia-Telangiectasia
11.1.4 Episodic Ataxia
11.1.5 Others (Multiple System Atrophy (MSA)
11.2 Ataxia Market by Service
11.2.1 Market Overview
11.2.2 Treatment
11.2.3 Diagnosis
11.3 Ataxia Market by Dosage Form
11.3.1 Market Overview
11.3.2 Solid
11.3.3 Liquids
11.3.4 Others
11.4 Ataxia Market by Age Group
11.4.1 Market Overview
11.4.2 Adult
11.4.3 Child
11.4.4 Geriatric
11.5 Ataxia Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Others
11.6 Ataxia Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 China
12 United States Ataxia Market
12.1 Ataxia Market Historical Value (2017-2023)
12.2 Ataxia Market Forecast Value (2024-2032)
12.3 Ataxia Market by Type
12.4 Ataxia Market by Service
13 EU-4 and United Kingdom Ataxia Market
13.1 Ataxia Market Historical Value (2017-2023)
13.2 Ataxia Market Forecast Value (2024-2032)
13.3 Germany Ataxia Market Overview
13.3.1 Ataxia Market by Type
13.3.2 Ataxia Market by Service
13.4 France Ataxia Market Overview
13.4.1 Ataxia Market by Type
13.4.2 Ataxia Market by Service
13.5 Italy Ataxia Market Overview
13.5.1 Ataxia Market by Type
13.5.2 Ataxia Market by Service
13.6 Spain Ataxia Market Overview
13.6.1 Ataxia Market by Type
13.6.2 Ataxia Market by Service
13.7 United Kingdom Ataxia Market Overview
13.7.1 Ataxia Market by Type
13.7.2 Ataxia Market by Service
14 Japan Ataxia Market
14.1 Ataxia Market Historical Value (2017-2023)
14.2 Ataxia Market Forecast Value (2024-2032)
14.2.1 Ataxia Market by Type
14.2.2 Ataxia Market by Service
15 China Ataxia Market
15.1 Ataxia Market Historical Value (2017-2023)
15.2 Ataxia Market Forecast Value (2024-2032)
15.2.1 Ataxia Market by Type
15.2.2 Ataxia Market by Service
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Novartis AG
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Merck KGaA
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Aurobindo Pharma
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Pfizer Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Sanofi
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Teva Pharmaceutical
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Acorda Therapeutics
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Viatris Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Design Therapeutics Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Lupin
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Apotex Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Biohaven Pharmaceuticals
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Amneal Pharmaceuticals LLC.
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Biovista
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 Intrabio
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
List not exhaustive
23 Ataxia Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 37.7 billion in 2023 driven by intensive research activities to develop effective drugs and therapies for ataxia patients across the 8 major markets.
The market is anticipated to grow at a CAGR of 9.72% during the forecast period of 2024-2032, likely to reach a market value of USD 95.3 billion by 2032.
The growing availability of pharmacological and other treatment alternatives like stem cell therapies to patients suffering from ataxia are the major factors aiding the market demand.
The surge in drug approvals by health authorities is one of the major trends driving the ataxia market. In February 2023, the United States Food and Drug Administration (FDA) approved Skyclarys as the first authorized treatment for Friedreich’s ataxia.
There are different types of ataxias, including spinocerebellar ataxias, ataxia-telangiectasia, and episodic ataxia, among others (multiple system atrophy (MSA)).
Based on the age group, the market is segmented into adult, child, and geriatric.
Based on the dosage forms, the market is divided into solids and liquids, among others.
The services in the market include treatment and diagnosis.
Major end users in the market include hospitals, and clinics, among others.
The major regions of the market include the United States, Japan, China, EU-4, and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.
Key players involved in the market are Novartis AG, Merck KGaA, Aurobindo Pharma, Pfizer Inc., Sanofi, Teva Pharmaceutical, Acorda Therapeutics, Viatris Inc., Design Therapeutics Inc., Lupin, Apotex Inc., Biohaven Pharmaceuticals, Amneal Pharmaceuticals LLC., Biovista, and Intrabio.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER